Cell-free DNA in newly diagnosed patients with glioblastoma – a clinical prospective feasibility study

Background: Glioblastoma (GB) is an incurable brain cancer with limited treatment options. The aim was to test the feasibility of using cell-free DNA (cfDNA) to support evaluation of treatment response, pseudo-progression and whether progression could be found before clinical and/or radiologic progression. Results: CfDNA fluctuated during treatment with the highest levels before diagnostic surgery and at progression. An increase was seen in 3 out of 4 patients at the time of progression while no increase was seen in 3 out of 4 patients without progression. CfDNA levels could aid in 3 out of 3 questionable cases of pseudo-progression. Methods: Eight newly diagnosed GB patients were included. Blood samples were collected prior to diagnosis, before start and during oncologic treatment until progression. Seven patients received concurrent radiotherapy/Temozolomide with adjuvant Temozolomide with one of the patients included in a clinical trial with either immunotherapy or placebo as add-on. One patient received radiation alone. CfDNA concentration was determined for each blood sample. Conclusions: It was feasible to measure cfDNA concentration. Despite the limited cohort size, there was a good tendency between cfDNA and treatment course and -response, respectively with the highest levels at progression.

[1]  C. Brennan,et al.  Tracking Tumor Evolution in Glioma through Liquid Biopsies of Cerebrospinal Fluid , 2018, Nature.

[2]  Keval Patel,et al.  Enhanced detection of circulating tumor DNA by fragment size analysis , 2018, Science Translational Medicine.

[3]  N. Ikuta,et al.  Prognostic utility of circulating nucleic acids in acute brain injuries , 2018, Expert review of molecular diagnostics.

[4]  F. Nielsen,et al.  Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors , 2018, Oncotarget.

[5]  P. Sorensen,et al.  The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner , 2018, Nature Communications.

[6]  B. Nahed,et al.  Blood-based biomarkers for the diagnosis and monitoring of gliomas. , 2018, Neuro-oncology.

[7]  K. Tsuchihara,et al.  Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients , 2018, Oncotarget.

[8]  P. Schirmacher,et al.  EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial , 2017, Virchows Archiv.

[9]  Mintu Pal,et al.  Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  James D. Brenton,et al.  Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.

[11]  L. Hui,et al.  Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: A qualitative study. , 2016, Gene.

[12]  Noah C Welker,et al.  Fragment Length of Circulating Tumor DNA , 2016, PLoS genetics.

[13]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[14]  M. Ychou,et al.  Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care , 2016, Clinical Cancer Research.

[15]  T. Wurdinger,et al.  Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer , 2015, Oncotarget.

[16]  Johnny Lo,et al.  Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma , 2015, Oncotarget.

[17]  V. Wong,et al.  Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients , 2015, Proceedings of the National Academy of Sciences.

[18]  A. Iafrate,et al.  Brain tumor cells in circulation are enriched for mesenchymal gene expression. , 2014, Cancer discovery.

[19]  L. Diaz,et al.  Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[21]  R. Kleszcz,et al.  Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients , 2013, Journal of Applied Genetics.

[22]  J. Egea-Guerrero,et al.  Role of early cell-free DNA levels decrease as a predictive marker of fatal outcome after severe traumatic brain injury. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[23]  Y. Marie,et al.  Detection of IDH1 mutation in the plasma of patients with glioma , 2012, Neurology.

[24]  M. Ychou,et al.  High Fragmentation Characterizes Tumour-Derived Circulating DNA , 2011, PloS one.

[25]  Klaus Pantel,et al.  Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.

[26]  P. Simon,et al.  Short-term treadmill running as a model for studying cell-free DNA kinetics in vivo. , 2011, Clinical chemistry.

[27]  M. Ychou,et al.  Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts , 2010, Nucleic acids research.

[28]  P. Wen,et al.  Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression , 2009, Journal of Neuro-Oncology.

[29]  C. Vrettou,et al.  Cell-free DNA levels in acute myocardial infarction patients during hospitalization , 2009, Acta cardiologica.

[30]  Dieta Brandsma,et al.  Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide , 2008, Cancer.

[31]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[32]  F. O. Fackelmayer,et al.  DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. , 2001, Cancer research.

[33]  P. Bottoni,et al.  The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects. , 2015, Advances in experimental medicine and biology.

[34]  Akihisa Kamataki,et al.  Characterization of circulating DNA in healthy human plasma. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[35]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.